

## Supporting Information

### **Design and radiosynthesis of a class-IIa HDAC inhibitor with high molar activity via repositioning the <sup>18</sup>F-radiolabel.**

**Sulan Xu<sup>1,2</sup>, Chun-Han Huang<sup>1,2,3</sup>, Christopher Eyermann<sup>1,4</sup>, Georgios V. Georgakis<sup>1,4</sup>, Nashaat Turkman\*<sup>1,2</sup>**


<sup>1</sup>Stony Brook Cancer Center, Stony Brook, Long Island, 11794, NY, USA

<sup>2</sup>Department of Radiology, School of Medicine, Stony Brook University, Long Island, 11794, NY, USA


<sup>3</sup>Department of Biomedical Engineering, Stony Brook University, Long Island, 11794, NY, USA

<sup>4</sup>Department of Surgery, School of Medicine, Stony Brook University, Long Island, 11794, NY, USA


<b>Table of Contents</b>	<b>Page</b>
<sup>1</sup> H NMR (CDCl <sub>3</sub> , 400 MHz), B) <sup>13</sup> C NMR and C) <sup>19</sup> F NMR (CDCl <sub>3</sub> , 376.5 MHz) spectrums for NT376	2
High resolution spectroscopy for NT376	4
Analytical radio-HPLC chromatograms of [ <sup>18</sup> F]8 and [ <sup>18</sup> F]9	5
Semi-preparative high performance liquid chromatography (HPLC) purification of [ <sup>18</sup> F]NT376	5
Analytical radio-HPLC chromatograms of purified [ <sup>18</sup> F]NT376 co-injected with authentic NT376	6
Resferences	6




**Figure 1.** A)  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz) and B)  $^{19}\text{F}$  NMR ( $\text{CDCl}_3$ , 376.5 MHz) spectroscopic characterization for NT376 was performed using 400 MHz Bruker instrument.




**Figure 2.** A)  $^{13}\text{C}$  NMR, full spectrum for NT376 ( $\text{CDCl}_3$ , 400 MHz) and B-D: expanded spectrum of chemical shifts from up to down field (provided for clarity).




**Figure 3.** High resolution mass spectroscopy (HRMS) for NT376 was performed using Agilent 1260HPLC/G6224A-TOF MS.




**Figure 4.** Analytical radio-HPLC chromatograms of [<sup>18</sup>F]NT8 co-injected with authentic 8. Samples were eluted with 70% acetonitrile/30% ammonium acetate buffer (20.0 mM) at a flow rate of 1.0 mL/min.




**Figure 5.** Analytical radio-HPLC chromatograms of [<sup>18</sup>F]9 which demonstrate complete conversion of [<sup>18</sup>F]8 to [<sup>18</sup>F]9. Samples were eluted with 70% acetonitrile/30% ammonium acetate buffer (20.0 mM) at a flow rate of 1.0 mL/min.




**Figure 6.** Semi-preparative high performance liquid chromatography (HPLC) purification of [<sup>18</sup>F]NT376 (a) radioactive peak of [<sup>18</sup>F]NT376 in crude mixture detected with radioactivity detector, (b) [<sup>18</sup>F]NT376 associated non-radioactive mass in the crude reaction mixture were detected with ultraviolet detector. Dashed lines shows start and stop of [<sup>18</sup>F]NT376 collection which demonstrate significant improvement in molar activity compared to our previous reports.<sup>1-3</sup>



**Figure 7.** Analytical radio-HPLC chromatograms of purified [<sup>18</sup>F]NT376: A) radioactive trace and B) ultraviolet mass trace for NT376 (note the Y-scale). Samples were eluted with 70% acetonitrile/30% ammonium acetate buffer (20.0 mM) at a flow rate of 1.0 mL/min.



**Figure 8.** Analytical radio-HPLC chromatograms of quality control for [<sup>18</sup>F]NT376: A) radioactive trace and B) co-injection with authentic NT376. Samples were eluted with 70% acetonitrile/30% ammonium acetate buffer (20.0 mM) at a flow rate of 1.0 mL/min.



**Figure 9.** Standard curve obtained for NT376 and was used to determine the molar activity.

(1) Turkman, N.; Xu, S.; Huang, C. H.; Eyermann, C.; Salino, J.; Khan, P. High-Contrast PET Imaging with [(18)F]NT160, a Class-IIa Histone Deacetylase Probe for In Vivo Imaging of Epigenetic Machinery in the Central Nervous System. *J Med Chem* **2023**, *66* (8), 5611-5621. DOI: 10.1021/acs.jmedchem.2c02064.

(2) Turkman, N.; Liu, D.; Pirola, I. Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy. *Eur J Med Chem* **2022**, *228*, 114011. DOI: 10.1016/j.ejmech.2021.114011.

(3) Turkman, N.; Liu, D.; Pirola, I. Novel late-stage radiosynthesis of 5-[18F]-trifluoromethyl-1,2,4-oxadiazole (TFMO) containing molecules for PET imaging. *Sci Rep* **2021**, *11* (1), 10668. DOI: 10.1038/s41598-021-90069-x.